PPT-Pharmacodynamic Profile of PL-ASA, a Novel Phospholipid-Aspirin Complex Liquid Formulation,

Franchi F Schneider DJ Prats J Fan W Rollini F Been L Taatjes Sommer HS Deliargyris EN Angiolillo DJ TCT 2021 Background Immediate release IR aspirin IRASA is associated with risk of mucosal damage in the upper gastrointestinal GI tract . Aspirin. Used as an analgesic (pain killer) for headaches, toothaches, neuralgia (nerve pain), muscle pain and joint pain.. Also effective as a fever reducer and anti-inflammatory.. Has anticoagulant properties – prevents strokes and heart attacks.. Cangrelor. . on . Platelet P2Y. 12. Receptor . Mediated Signaling . in . Prasugrel. Treated Patients. Fabiana Rollini, . Francesco Franchi, . Antonio . Tello-Montoliu, Ronakkumar Patel, Andrew Darlington, . Aspirin. perhaps most popular medicinal agent ever discovered. 30 000 000 . lb. /year sold in the US. Antipyretic (reduces fever). Anti-inflammatory (reduces . swelling suppresses prostaglandin hormone). Chapter 14. Aspirin. Pharmaceutical products are often developed from substance found in a plant that has been used for traditional medicine.. Aspirin is one of these products.. Salicylic acid is the active substance that helps . Thromboembolism. N . Engl. J Med. 2012;366:1959-67. VTE Prevalence. Incidence . of DVT: 48 per 100,000. Incidence of PE: 23 per 100,000. Case-fatality rate. Inpatient: 12%. 1-year: 19%; 3-year: 30%. (EINSTEIN CHOICE). Ryan Sparks, . PharmD. , BCPS. PGY2 Cardiology Resident. WakeMed. Health & . Hosptials. Raleigh, NC. Dr. . Ryan Sparks (presenter). Current PGY2 Cardiology Resident at . WakeMed. Team members: . Heather . Addy. , Anna Davis, Cindy Graham, Joan Marshall, Vesal Mahanian. Membrane Structure and Function. 26 July 2012. Learning Goals. Understand why phospholipids spontaneously arrange into micelles and vesicles when mixed in water. ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage and Louise Bowman on behalf of the ASCEND Study Collaborative Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial Kelley Branch, MD, MSc, on behalf of the COMPASS Steering Committee and Investigators Original Article Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism Timothy A. Brighton, M.B., B.S., John W. Eikelboom, M.B., B.S., Kristy Mann, M.Biostat., Rebecca Mister, M.Sc., Alexander Gallus, M.B., B.S., Paul Ockelford, M.B., Harry Gibbs, M.B., Wendy Hague, Ph.D., Denis Xavier, M.Sc., Rafael Diaz, M.D., Adrienne Kirby, M.Sc., John Simes, M.D., for the ASPIRE Investigators Primary Prevention ASCVD. Jennifer Bannon RN BSN MSHI. Table of Contents. Objectives . Cardiovascular Disease. Cardiovascular Disease (2). ABCS-Aspirin when appropriate. Anatomy of a Performance Measure. as salicylic acid and its derivatives e.g. aspirin, and . paracetamol. , . block the transmission of pain from source . i.e. the injured tissue to . brain as they intercept the pain stimulus . at source. . SOMA Soma ( Soma Compound w/Codeine (carisoprodol and aspirin and codeine) Soma FEP Clinical Rationale RATIONALE FOR INCLUSION IN PA PROGRAM Background Soma , Soma Compound, and Soma Compound with ORIGIN. Pierre . Amarenco. , Hans . Denison. , . Scott R. Evans, Anders . Himmelmann. , Stefan James, Mikael . Knutsson. , . Per . Ladenvall. , Carlos . A. Molina. , . Yongjun. Wang. , S. . Claiborne .